The FDA notified healthcare professionals of the risk of serious liver injury, including liver failure and death, with the use of propylthiouracil (PTU) in adult and pediatric patients. The FDA has identified 32 cases (22 adult and 10 pediatric) of serious liver injury associated with propylthiouracil use. Although PTU is used for the treatment of hyperthyroidism resulting from Graves’ disease, healthcare professionals should carefully consider whether to initiate treatment of it in patients recently diagnosed with the disease. Physicians should closely monitor patients on PTU therapy for symptoms and signs of liver injury, especially during the first six months of therapy. Propylthiouracil should not be used in pediatric patients unless the patient is allergic to or intolerant of methimazole, and there are no other treatment options available.
Posted by SharonD
Related posts:
- Psoriasis Drug Recalled Due to Risk of Neurological Disease
- Study: “Jawbone Death” Linked to Fosamax
- FDA Issues Warning on Actos
- Major Warnings Issued for Reglan, Metoclopramide
- What is Wrongful Death?
Tags: Graves' disease, liver failure, propylthiouracil, PTU
